1. 107PPhase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. (25th November 2018) Authors: Kagawa, Y; Satake, H; Kato, T; Oba, K; Yasui, H; Nakamura, M; Watanabe, T; Hirata, K; Muro, K; Komatsu, Y; Yoshino, T; Yamazaki, K; Mishima, H; Kotaka, M; Tsuji, A; Kakeji, Y; Oki, E; Nagata, N; Junichi, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1275PPhase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma. (23rd October 2018) Authors: Nomura, M; Andoh, M; Yokota, T; Miyazaki, T; Satake, H; Iwasawa, S; Sonoda, A; Kato, K; Muto, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 467PProspective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer. (23rd October 2018) Authors: Masuishi, T; Suzuki, T; Sukawa, Y; Imamura, C K; Satake, H; Kumekawa, Y; Funakoshi, S; Kotaka, M; Horie, Y; Kawai, S; Okuda, H; Terazawa, T; Kondoh, C; Kato, K; Yoshimura, K; Ishikawa, H; Hamamoto, Y; Boku, N; Kanai, T; Takaishi, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 480PThe safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective study. (23rd October 2018) Authors: Ogata, T; Satake, H; Ogata, M; Hatachi, Y; Hamada, M; Yasui, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 481PPhase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial. (23rd October 2018) Authors: Osawa, H; Shinozaki, E; Nakamura, M; Ohhara, Y; Shindo, Y; Shiozawa, M; Uetake, H; Matsumoto, H; Ureshino, N; Satake, H; Kobayashi, T; Suto, T; Kitano, S; Ohashi, Y; Uemura, K; Yamaguchi, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 535PSafety and effectiveness of oral rivaroxaban for the treatment of venous thromboembolism in cancer patients. (22nd November 2017) Authors: Kondo, Y; Hirabatake, M; Satake, H; Yasui, H; Hashida, T Journal: Annals of oncology Issue: Volume 28(2017)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 599PEfficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study. (23rd October 2018) Authors: Kato, T; Kotaka, M; Satake, H; Makiyama, A; Tsuji, Y; Shinozaki, K; Fujiwara, T; Mizushima, T; Harihara, Y; Nagata, N; Kurihara, N; Kagawa, Y; Kusakawa, G; Sakai, T; Uchida, Y; Takamoto, M; Asami, S; Ando, M; Saito, Y; Hyodo, I Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 670PPhase II study of S-1 and oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601). (23rd October 2018) Authors: Kobayashi, K; Iwatsuki, M; Orita, H; Hidaka, S; Arigami, T; Kusumoto, T; Satake, H; Oki, E; Satoshi, K; Tobimatsu, K; Shimokawa, M; Saeki, H; Makiyama, A; Kakeji, Y; Natsugoe, S; Baba, H; Eguchi, S; Maehara, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 731PPhase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). (23rd October 2018) Authors: Takahashi, H; Morizane, C; Nomura, S; Okano, N; Tsuda, M; Mizuno, N; Satake, H; Tsuji, K; Shioji, K; Ishii, H; Yasui, K; Miyakawa, H; Ishiguro, A; Ogura, T; Ueno, M; Ikeda, A; Terashima, T; Ikeda, M; Okusaka, T; Furuse, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 762PA randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208). (23rd October 2018) Authors: Terajima, H; Kobayashi, S; Nagano, H; Tomokuni, A; Gotoh, K; Sakai, D; Hatano, E; Seo, S; Uchida, Y; Ajiki, T; Satake, H; Kamei, K; Tohyama, T; Hirose, T; Ikai, I; Morita, S; Ioka, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗